Journal Home
Search for

Volume 43, Issue 5, Pages 421-424 (November 2008)


View previous. 4 of 19 View next.

A Review of Adapalene in the Treatment of Acne Vulgaris

Cynthia E. Irby, B.A.a, Brad A. Yentzer, M.D.a, Steven R. Feldman, M.D., Ph.D.abcCorresponding Author Informationemail address

Received 7 January 2008; accepted 9 June 2008.

Abstract 

Topical retinoids help address the early lesions of acne vulgaris. Consensus guidelines advocate the use of topical retinoids as the primary treatment for most forms of acne vulgaris. However, all topical retinoid preparations may be irritating, and this may contribute to underutilization in clinical practices. Topical adapalene fosters topical retinoid treatment of acne with less irritation. Adapalene is a more stable molecule than tretinoin. Adapalene can be used without concern for photo-deactivation. Because of its chemical stability, adapalene can be used in combination with benzoyl peroxide products. The availability of a stable topical retinoid associated with little irritation may facilitate meeting acne treatment consensus guidelines.

a Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine; Winston-Salem, North Carolina

b Department of Public Health Sciences, Center for Dermatology Research, Wake Forest University School of Medicine; Winston-Salem, North Carolina

c Department of Pathology, Center for Dermatology Research, Wake Forest University School of Medicine; Winston-Salem, North Carolina

Corresponding Author InformationAddress correspondence to: Steven R. Feldman, M.D., Ph.D., Department of Dermatology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1071

 Potential conflicts of interest: Dr. Feldman has received research, speaking and/or consulting support from several manufacturers of topical retinoids including Galderma, OrthoNeutrogena, and Stiefel. The Center for Dermatology Research is supported by an educational grant from Galderma Laboratories, L.P. Dr. Yentzer and Ms. Irby have no conflicts to disclose.

PII: S1054-139X(08)00271-1

doi:10.1016/j.jadohealth.2008.06.005


View previous. 4 of 19 View next.